Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of KLT-1101 in advanced solid tumors receiving chemotherapy
CTR20201221Phase 2Active
- Sponsor
- Kanglitai Pharmaceutical
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of KLT-1101 in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), sponsored by Kanglitai Pharmaceutical. Started Dec 2020; status: active.
02
Drugs
KLT-1101
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20201221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201221.